Pulmonx Corp
No enriched coverage for $LUNG in the last 7 days.
No SEC Form 4 filings for $LUNG in the last 30 days.
See all $LUNG insider activity →Pulmonx (LUNG) stock fell 10.1% in pre-market trading to $2.05, with no clear catalyst. The decline follows a recent rally from its 52-week low, and profit-taking is a possible reason. The company's Q2 2026 earnings showed a 5% revenue decline, and analysts remain cautious. Broader market weakness also contributed to the drop.
Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
Recent LUNG coverage spans financial news, market movers and earnings.
The drop is likely short‑term and driven by technical sell‑off rather than new fundamentals.
Guidance reaffirmation plus improved loss profile can sustain the bid, especially for traders tracking revenue trajectory.
Improving losses despite revenue softness can attract buyers focused on operating leverage and downside control.
Margin expansion and loss narrowing, plus reaffirmed full-year revenue and gross margin guidance, are likely supportive for near-term sentiment despite modest top-line decline.
The earnings release provides fresh quarterly datapoints and updated full-year guidance, which can drive near-term repricing of LUNG’s growth and margin trajectory.
AlphAI scores every news story that mentions LUNG with an AI model for sentiment and relevance, and aggregates insider trades from Pulmonx Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Pulmonx (LUNG) stock fell 10.1% in pre-market trading to $2.05, with no clear catalyst. The decline follows a recent rally from its 52-week low, and profit-taking is a possible reason. The company's Q2 2026 earnings showed a 5% revenue decline, and analysts remain cautious. Broader market weakness also contributed to the drop.
1 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min readPulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.
4 min readPulmonx (Nasdaq: LUNG) reported Q2 2026 revenue of $22.8 million, down 5% year over year, with U.S. revenue at $14.2 million (-4%) and international at $8.6 million (-6%). Gross margin rose to 78%. Net loss was $10.1 million, down from $15.2 million. Full-year 2026 revenue guidance is $90 million to $92 million.
6 min readPulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon
3 min readBlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 765,721 shares of Pulmonx Corp common stock, or 1.8% of the class. The filing states BlackRock has sole voting and sole dispositive power over the shares, with no shared power. It also notes underlying clients may receive dividends or sale proceeds.
2 min readPulmonx Corp (LUNG) reported its Q1 2026 results, surpassing revenue and EPS estimates with $20.6 million in revenue and a GAAP EPS of -$0.33. Despite a 9% year-over-year revenue decline, the company saw gross margin expand to 78% and attributed international declines to a temporary registration pause in China. GuruFocus considers LUNG 85.3% undervalued, trading at a significant discount to its intrinsic value.
3 min readPulmonx Corp (LUNG) has reaffirmed its 2026 revenue guidance, projecting between $90 million and $92 million, with a robust gross margin near 75%. Despite anticipated operating expenses between $113 million and $115 million, the company, which specializes in minimally invasive treatments for severe emphysema, shows strength in growth but has concerns regarding profitability and financial stability. Its GF Score™ of 59 and a low price-to-sales ratio of 0.55 suggest potential undervaluation, though caution is advised due to insider selling and financial health indicators.
2 min readPulmonx (LUNG) reported mixed financial results for Q1 2026, with an EPS of -$0.33, beating estimates, but revenue of $20.6 million, missing forecasts. The stock dropped 0.81% in aftermarket trading, nearing its 52-week low, due to investor concerns over the revenue miss and continued net losses. Despite the challenges, the company is focused on re-accelerating U.S. sales, advancing its AeriSeal program to expand its market, and aligning its cost structure for profitability, with management expressing confidence in returning to double-digit growth by year-end.
4 min read